Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2001-08-10
2003-05-20
McKane, Joseph K. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S133000, C544S176000, C546S245000, C548S215000, C548S240000, C548S540000
Reexamination Certificate
active
06566553
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates generally to methods for preparing lactacystin and related compounds, to novel analogs of lactacystin and clasto-lactacystin &bgr;-lactone, and their uses as proteasome inhibitors.
2. Description of Related Art
The Streptomyces metabolite lactacystin (1) inhibits cell cycle progression and induces neurite outgrowth in cultured neuroblastoma cells (Omura et al.,
J. Antibiotics
44:117 (1991); Omura et al.,
J. Antibiotics
44:113 (1991); Fenteany et al.,
Proc. Natl. Acad. Sci. (USA)
91:3358 (1994)). The cellular target mediating these effects is the 20S proteasome, the proteolytic core of the 26S proteasome, which is the central component of the ubiquitin-proteasome pathway for intracellular protein degradation. Mechanistic studies have established that lactacystin inhibits the proteasome through the intermediacy of the active species, clasto-lactacystin &bgr;-lactone (2), which specifically acylates the N-terminal threonine residue of the proteasome X/MB1 subunit (Fenteany, et al.,
Science
268:726 (1995); Dick et al.,
J. Biol. Chem.
271:7273 (1996)). Lactacystin analogs are disclosed by Fenteany et al. (WO 96/32105).
The ubiquitin-proteasome pathway is involved in a variety of important physiological processes (Goldberg et al.,
Chemistry
&
Biology
2:503 (1995); Ciechanover
Cell
79:13 (1994); Deshaies,
Trends Cell Biol.
5:43 1 (1995)). In fact, the bulk of cellular proteins are hydrolyzed by this pathway. Protein substrates are first marked for degradation by covalent conjugation to multiple molecules of a small protein, ubiquitin. The resultant polyubiquitinated protein is then recognized and degraded by the 26S proteasome. Long recognized for its role in degradation of damaged or mutated intracellular proteins, this pathway is now also known to be responsible for selective degradation of various regulatory proteins. For example, orderly cell cycle progression requires the programmed ubiquitination and degradation of cyclins. The ubiquitin-proteasome pathway also mediates degradation of a number of other cell cycle regulatory proteins and tumor suppressor proteins (e.g., p21, p27, p53). Activation of the transcription factor NF-&kgr;B, which plays a central role in the regulation of genes involved in the immune and inflammatory responses, is dependent upon ubiquitination and degradation of an inhibitory protein, I&kgr;B-&agr; (Palombella et al., WO 95/25533). In addition, the continual turnover of cellular proteins by the ubiquitin-proteasome pathway is essential to the processing of antigenic peptides for presentation on MHC class I molecules (Goldberg and Rock, WO 94/17816).
The interesting biological activities of lactacystin and clasto-lactacystin &bgr;-lactone and the scarcity of the natural materials, as well as the challenging chemical structures of the molecules, have stimulated synthetic efforts directed toward lactacystin and related analogs. Corey and Reichard
J. Am. Chem. Soc.
114:10677 (1992);
Tetrahedron Lett.
34:6977 (1993)) achieved the first total synthesis of lactacystin, which proceeded in 15 steps and 10% overall yield. The key feature of the synthesis is a stereoselective aldol reaction of a cis-oxazolidine aldehyde derived from N-benzylserine to construct the C(6)-C(7) bond. In the synthesis reported by (Uno et al.,
J. Am. Chem. Soc.
116:2139 (1994)), stereo selective Mukaiyama-aldol reaction of a bicyclic oxazolidine silyl enol ether intermediate derived from D-pyroglutamic acid is employed in C(5)-C(9) bond construction. This synthesis proceeds in 19 steps and 5% overall yield. Aldol reactions under basic conditions of a similar bicyclic oxazolidine intermediate form the basis of model studies reported by (Dikshit et al.,
Tetrahedron Lett.
36:6131 (1995)).
Aldol reactions of oxazoline-derived enolates feature prominently in the synthesis of lactacystin reported by Smith and coworkers (Suazuka et al.,
J. Am. Chem. Soc.
115:5302 (1993); Nagamitsu et al.,
J. Am. Chem. Soc.
118:3584 (1996)) and in the synthesis of (6R)-lactacystin reported by (Corey and Choi
Tetrahedron Lett.
34:6969 (1993)); Choi Ph.D., Thesis, Harvard University, 44 (1995). In the former synthesis, which proceeds in 20 steps and 9% overall yield, the enolate is condensed with formaldehyde to install a single carbon atom, which must then be elaborated in a number of additional steps. In the Corey and Choi synthesis, the aldol reaction selectively provides the product of undesired stereochemistry, resulting in the eventual preparation of the C(6) epimer of lactacystin, which is devoid of biological activity.
Lactacystin has also been prepared in 22 steps and 2% overall yield from D-glucose (Chida et al.,
J. Chem. Soc., Chem. Commun.
793 (1995)). The biosynthetic pathway involved in production of the natural product has been investigated in feeding experiments involving
13
C-enriched compounds (Nakagawa et al.,
Tetrahedron Lett.
35:5009 (1994)).
The reported syntheses of lactacystin are lengthy and proceed in low yield. Furthermore, none of these syntheses is readily adapted for analog synthesis. Thus, there is a need for improved methods for preparing lactacystin, clasto-lactacystin &bgr;-lactone, and analogs thereof
SUMMARY OF THE INVENTION
A first aspect of the present invention relates to a process for forming lactacystin or analogs thereof having Formula VI or clasto-lactacystin &bgr;-lactone or analogs thereof having Formula VII:
wherein
R
1
is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkaryl, aralkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted;
R
2
is alkyl, cycloalkyl, aryl, alkaryl, aralkyl, alkoxy, hydroxy, alkoxyalkyl, or amido, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted; and
R
7
is alkyl, aryl, aralkyl, alkaryl, wherein any of said alkyl, aryl, aralkyl or alkaryl can be optionally substituted.
A second aspect of the present invention is directed to a method of forming formyl amides of Formula XIV:
where R
2
is alkyl, cycloalkyl, aryl, alkaryl, aralkyl, alkoxy, hydroxy, alkoxyalkyl, or amido, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted; and
R
5
and R
6
are independently one of alkyl or alkaryl; or R
5
and R
6
when taken together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring, which may be optionally substituted, and which optionally may include an additional oxygen or nitrogen atom.
A third aspect of the present invention relates to forming tri-substituted oxazolines of Formula Ia or Ib:
where R
1
is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkaryl, aralkyl, where the ring portion of any of said aryl, aralkyl, or alkaryl can be optionally substituted; and R
4
is aryl or heteroaryl, either of which may be optionally substituted. The tri-substituted oxazolines of Formulae Ia and Ib are useful as starting materials in forming lactacysin, clasto-lactacystin &bgr;-lactone or analogs thereof via the process described herein.
A fourth aspect of the present invention is directed to lactacysin, clasto-lactacystin &bgr;-lactone or analogs of Formulae VI and VI that possess unexpected biological activity. Lactacystin, clasto-lactacystin &bgr;-lactone, and analogs thereof possess biological activity as inhibitors of the proteasome. They can be used to treat conditions mediated directly by the function of the proteasome, such as muscle wasting, or mediated indirectly via proteins which are processed by the proteasome, such as the transcription factor NF-&kgr;B.
A fifth aspect of the present invention relates to pharmaceutical compositions, comprising a compound of Formula VI or Formula VII, and a pharmaceutically acceptable carrier or diluent.
A sixth aspect of the present invention relates to methods of inhibiting proteasome function or treating a condition that is mediated directly or indirectly by the function of the proteasome, by administering a compound of Formula VI o
Behnke Mark
Plamondon Louis
Roush William
Soucy François
Hale and Dorr LLP
Millennium Pharmaceuticals Inc.
Saeed Kamal
LandOfFree
Synthesis of clasto-lactacystin &bgr;-lactone and analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of clasto-lactacystin &bgr;-lactone and analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of clasto-lactacystin &bgr;-lactone and analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3053211